In Silico Models using Artificial IntelligenceAriana Pharma offers access to its Artificial Intelligence Platform for the access and analysis of the IMODI knowledge bases.
Using the extensive data collected through the IMODI network, Ariana generates multi-component signatures that combine clinical, biochemical and molecular data generated across multiple biological models: tumor samples, cell lines, or patient derived xenografted mice. These models are further enriched using publicly available databases.
These models help identify new indications for existing drugs, further our molecular understanding of their mode of action and help characterize novel therapeutic targets.
Going beyond Cancer, Ariana’s expertise spans multiple therapeutic areas, including, Alzheimer and other neurodegenerative diseases, rheumatologically and immunological diseases, etc. A broad variety of data types can be combined, including clinical and demographic, pharmacokinetics, pharmacodynamics, biochemical measurements, NGS genetic and genomic, including microbiota, proteomics, metabolomics and radiomics. Multiple endpoints and time series can be integrated in the model building steps.
Ariana Pharma is a leading digital health Company focused on developing advanced therapeutic decision support systems. Ariana’s innovative clinical data analysis and diagnostic testing solutions help the healthcare sector better adapt patient treatments to individual biological characteristics. Ariana KEM® Artificial Intelligence technology enables personalization of therapies, improves the efficacy and safety of patient treatment, reduces risks and drug development costs, and accelerates time to market. With a growing number of successful therapeutic development applications, KEM® is the only FDA-tested technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology treatment selection system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012. Further information is available at www.arianapharma.com.